JP2023500337A5 - - Google Patents
Info
- Publication number
- JP2023500337A5 JP2023500337A5 JP2022525913A JP2022525913A JP2023500337A5 JP 2023500337 A5 JP2023500337 A5 JP 2023500337A5 JP 2022525913 A JP2022525913 A JP 2022525913A JP 2022525913 A JP2022525913 A JP 2022525913A JP 2023500337 A5 JP2023500337 A5 JP 2023500337A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogenic composition
- seq
- vaccine
- acid sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026002786A JP2026074006A (ja) | 2019-11-04 | 2026-01-09 | 脳がんを治療するための併用療法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930417P | 2019-11-04 | 2019-11-04 | |
| US62/930,417 | 2019-11-04 | ||
| US202062988102P | 2020-03-11 | 2020-03-11 | |
| US62/988,102 | 2020-03-11 | ||
| US202063018060P | 2020-04-30 | 2020-04-30 | |
| US63/018,060 | 2020-04-30 | ||
| US202063070987P | 2020-08-27 | 2020-08-27 | |
| US63/070,987 | 2020-08-27 | ||
| PCT/US2020/058891 WO2021092019A1 (en) | 2019-11-04 | 2020-11-04 | Combination therapy to treat brain cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002786A Division JP2026074006A (ja) | 2019-11-04 | 2026-01-09 | 脳がんを治療するための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500337A JP2023500337A (ja) | 2023-01-05 |
| JP2023500337A5 true JP2023500337A5 (enExample) | 2023-11-13 |
| JP7882776B2 JP7882776B2 (ja) | 2026-06-30 |
Family
ID=75686760
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525913A Active JP7882776B2 (ja) | 2019-11-04 | 2020-11-04 | 脳がんを治療するための併用療法 |
| JP2026002786A Pending JP2026074006A (ja) | 2019-11-04 | 2026-01-09 | 脳がんを治療するための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026002786A Pending JP2026074006A (ja) | 2019-11-04 | 2026-01-09 | 脳がんを治療するための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210128710A1 (enExample) |
| EP (1) | EP4055033A4 (enExample) |
| JP (2) | JP7882776B2 (enExample) |
| KR (1) | KR20220097928A (enExample) |
| CN (1) | CN114901677A (enExample) |
| AU (2) | AU2020380288B2 (enExample) |
| BR (1) | BR112022008164A2 (enExample) |
| CA (1) | CA3156227A1 (enExample) |
| CO (1) | CO2022007361A2 (enExample) |
| IL (1) | IL292462A (enExample) |
| MX (1) | MX2022005345A (enExample) |
| PH (1) | PH12022551078A1 (enExample) |
| WO (1) | WO2021092019A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548746A (ja) | 2020-10-13 | 2023-11-21 | クリヤ セラピューティクス インコーポレイテッド | サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用 |
| CN113447654B (zh) * | 2021-07-15 | 2022-03-22 | 广州济士源生物技术有限公司 | 质谱技术检测尿液中psm-e分子水平在制备用于早期诊断前列腺癌产品中的应用 |
| WO2023019240A2 (en) * | 2021-08-13 | 2023-02-16 | Inovio Pharmaceuticals Inc. | Combination therapy to treat brain cancer |
| US11526994B1 (en) * | 2021-09-10 | 2022-12-13 | Neosoma, Inc. | Labeling, visualization, and volumetric quantification of high-grade brain glioma from MRI images |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833754B2 (en) * | 2006-01-13 | 2010-11-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | IL-12 for expression in mammalian cell |
| IL298125A (en) * | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| EP4086285A1 (en) * | 2016-02-25 | 2022-11-09 | Cell Medica Switzerland AG | Binding members to pd-l1 |
| CN110050062A (zh) * | 2016-08-09 | 2019-07-23 | 阿尔莫哈纳德·阿尔卡亚尔 | 表达il12的溶瘤弹状病毒 |
| AU2017336088B2 (en) * | 2016-09-30 | 2023-07-06 | Inovio Pharmaceuticals, Inc. | Tert immunogenic compositions and methods of treatment using the same |
| EA201990624A1 (ru) * | 2017-03-07 | 2019-09-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Иммуногенные композиции tert и способы лечения с их использованием |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| KR102702230B1 (ko) * | 2017-05-26 | 2024-09-03 | 에피센트알엑스, 인코포레이티드 | 트랜스진을 보유하는 재조합 아데노바이러스 |
| CN109486828B (zh) * | 2018-12-27 | 2022-05-31 | 广东暨大基因药物工程研究中心有限公司 | 一种编码重组人白细胞介素12的基因及其应用 |
| CA3136568A1 (en) * | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| WO2021051065A1 (en) * | 2019-09-12 | 2021-03-18 | Inovio Pharmaceuticals, Inc. | Tert, wt-1, pmsa immunogenic compositions and methods of treatment using the same |
| NZ786589A (en) * | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
-
2020
- 2020-11-04 US US17/089,244 patent/US20210128710A1/en active Pending
- 2020-11-04 BR BR112022008164A patent/BR112022008164A2/pt unknown
- 2020-11-04 AU AU2020380288A patent/AU2020380288B2/en not_active Ceased
- 2020-11-04 CA CA3156227A patent/CA3156227A1/en active Pending
- 2020-11-04 EP EP20884253.4A patent/EP4055033A4/en active Pending
- 2020-11-04 PH PH1/2022/551078A patent/PH12022551078A1/en unknown
- 2020-11-04 MX MX2022005345A patent/MX2022005345A/es unknown
- 2020-11-04 KR KR1020227018389A patent/KR20220097928A/ko not_active Ceased
- 2020-11-04 JP JP2022525913A patent/JP7882776B2/ja active Active
- 2020-11-04 CN CN202080088086.1A patent/CN114901677A/zh active Pending
- 2020-11-04 WO PCT/US2020/058891 patent/WO2021092019A1/en not_active Ceased
- 2020-11-04 IL IL292462A patent/IL292462A/en unknown
-
2022
- 2022-05-27 CO CONC2022/0007361A patent/CO2022007361A2/es unknown
-
2024
- 2024-04-30 AU AU2024202791A patent/AU2024202791A1/en not_active Abandoned
-
2026
- 2026-01-09 JP JP2026002786A patent/JP2026074006A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510964A5 (enExample) | ||
| Salvin et al. | Brief communication: tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity | |
| US11932688B2 (en) | Treatment for neoplastic diseases | |
| JP2019517549A5 (enExample) | ||
| JP2024531151A5 (enExample) | ||
| AU2012312225B2 (en) | Cachexia treatment | |
| AU2024354737A1 (en) | Combination therapy for cancer treatment | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| AR091462A1 (es) | Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso | |
| JP2024527607A5 (enExample) | ||
| JP2022515770A5 (enExample) | ||
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| JP2023545084A5 (enExample) | ||
| Nicolin et al. | Cellular immune response to a drug-treated L5178Y lymphoma subline | |
| JP2024533067A5 (enExample) | ||
| JP2024516698A5 (enExample) | ||
| JP2020500161A5 (enExample) | ||
| JP2022513029A5 (enExample) | ||
| JP2025509567A5 (enExample) | ||
| CN111166878A (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| JP2022534494A5 (enExample) | ||
| JP2019535716A5 (enExample) | ||
| JP2024542879A5 (enExample) | ||
| JP2024537298A5 (enExample) | ||
| IL310808A (en) | Combination therapy to treat brain cancer |